Navigation Links
Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
Date:10/31/2013

TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 1, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that it has appointed Erik Penser Bankaktiebolag as a liquidity provider  for the Company's common shares currently listed on NASDAQ OMX Stockholm Exchange  under the trading symbol IMNP. The firm will continue to be the Company's liquidity provider after its planned transfer of its stock listing from NASDAQ OMX Stockholm Exchange to NASDAQ OMX First North Premier.

A liquidity provider facilitates the buying and selling of shares in order to narrow the difference between the bid and ask prices of a traded security.  The liquidity provider's goal is to reduce market risk, enabling shareholders to more efficiently trade in the Company's common stock.  The agreement between Erik Penser Bankaktiebolag and the Company is consistent with the terms established by NASDAQ OMX in Stockholm for liquidity providers pertaining to both the NASDAQ OMX Stockholm Exchange and NASDAQ OMX First North Premier.  The agreement is effective as of November 1, 2013.

About Erik Penser Bankaktiebolag

Erik Penser Bankaktiebolag is a privately owned and independent bank that offers a broad range of financial services to private and institutional investors and focuses on creating value for its clients. Erik Penser Bankaktiebolag has approximately 90 employees and has its office at Biblioteksgatan 9 in Stockholm, Sweden. Erik Penser Bankaktiebolag operates under the supervision of the Swedish Financial Supervisory Authority and is a member of the leading Nordic exchanges, SwedSec and the Swedish Securities Dealers Association

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) applies a personalized approa
'/>"/>

SOURCE Immune Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
2. Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets
3. InterMune to Divest Actimmune® (Interferon Gamma-1b)
4. ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer
5. MedImmune and WuXi AppTec Announce Joint Venture to Develop Novel Biologic for Chinese Market
6. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
7. Easy on the Stomach: ALCAT Worldwide Sponsors Successful Conference on Gut, Brain & Autoimmune Disorders
8. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
9. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
10. Natural Tree Extract (Larch Arabinogalactan) Shown to Have Statistically Significant Effect in Protecting Immune Health
11. Remique (TM), a Revolutionary Dietary Supplement, Manufactured in FDA Registered Facilities, Receives Raves from Compromised Immune System Sufferers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Surefire Medical ... infusion systems designed to maximize targeted delivery of embolization ... to announce that oncologist John R. Daniels , ... Cancer Center, and surgical oncologist Steven C. Katz ... joined the Company,s Scientific Advisory Board (SAB).    ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, ... today announced they have entered into a license ... designed to target cancers. PhosImmune possesses ... on the surfaces of tumor cells in association ... derived from proteins that play a role in ...
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... quickly add weight and length may be showing a genetic ... In adults, certain genes have been linked to increased body ... in fat and lean muscle, the researchers said. At ... taller. By ages 2 and 3, however, these genes were ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... part of conventional in vitro fertilization (IVF) -- the incubation ... place in a device inside the vagina, new research suggests. ... the device, called an INVOcell, might sharply cut costs for ... the technology more accessible to those who don,t live near ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The newly ... must-have source of thousands of facts, figures and forecasts ... and 68 medical sector forecast categories the Worldwide ... global, regional and national views on the worldwide medical ... , The report gives you data for 2010-2019, covering ...
(Date:10/20/2014)... October 20, 2014 ASCNYC (ascnyc.org) ... that helps New Yorkers living with HIV/AIDS and ... health, housing, recovery and self-sufficiency. Each year, ASCNYC ... local community through their tireless efforts. , ... Shapses , has been selected as this year’s ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... can worsen the impact of asthma and may also mask ... Zealand, who studied lung function in asthmatic women with a ... first prospective study to reveal a significant comparative difference in ... attack in obese and non-obese individuals. , The research ...
... Trust, Inc.,(NYSE: BMR ), a real estate investment trust focused ... results for,the first quarter ended March 31, 2008., Highlights:, ... million, or $0.46 per diluted share, ... share, equivalent to an annualized common stock ...
... Brookdale Senior,Living Inc. (NYSE: BKD ) announced ... financial results after the market closes on Wednesday, May ... discuss the results on,Thursday, May 8, 2008 at 8:00 ... (866) 845-7252 (from within the U.S.) or (706) 634-9069 ...
... 30 New data is showing a dramatic,reduction ... in this country.,Here,s more on one group,s 20-year ... to this report from Safe Kids Worldwide at:, ... audio, text, graphics and,photos for free and unrestricted ...
... eligible Medicaid members, PHOENIX, April 30 ... law, allowing the state Medicaid program to,expend moneys ... Introduced by Sen. Barbara Leff (R-Paradise Valley), ... state,s General Fund and will provide benefits,for nicotine ...
... in relapsing remitting illness , , WEDNESDAY, April 30 (HealthDay ... people with the relapsing remitting form of multiple sclerosis ... the disease were randomly selected to receive either 20 ... for 24 weeks. MRI brain scans were conducted every ...
Cached Medicine News:Health News:Obesity worsens impact of asthma 2Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 2Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 3Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 4Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 5Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 6Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 7Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 8Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 9Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 10Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 11Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 12Health News:BioMed Realty Trust Reports First Quarter 2008 Financial Results 13Health News:Brookdale Announces First Quarter 2008 Release and Earnings Call 2Health News:Governor Napolitano Signs Smoking Cessation Bill 2Health News:Prozac Reduces Disease Activity in MS Patients 2
Fine abrasive for knife sharpening, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Standard knife with box, C profile...
... stage is a refrigerated design for use as ... use with the 8000 sledge microtome, however, it ... refrigerated stage gives a large working area of ... to provide good adhesion between the specimen and ...
Medicine Products: